Skip to main content



09-13-2017 | Acarbose | EASD 2017 | News

ACE results suggest no reduction in CV risk with acarbose treatment

The α-glucosidase inhibitor acarbose does not reduce cardiovascular risk but could decrease the risk for developing type 2 diabetes among patients with coronary heart disease and impaired glucose tolerance, results of the phase IV placebo-controlled ACE trial suggest.

Read more

Related topics



Journal articles and book chapters

06-24-2016 | Medications | Review | Article

Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus

A review of the pharmacokinetics, pharmacodynamics and safety profiles, including cardiovascular safety, of currently available therapies for management of hyperglycemia in patients with type 2 diabetes.

Nat Rev Endocrinol 2016;12:566–592. doi:10.1038/nrendo.2016.86

Abd A. Tahrani, Anthony H. Barnett, Clifford J. Bailey

12-01-2015 | Diabetic complications | Review | Article

Management of diabetes mellitus in patients with chronic kidney disease

Glycemic control is essential in delaying or preventing the onset of diabetic kidney disease. There are a number of glucose-lowering medications available, but only a fraction of them can be used safely in chronic kidney disease and many of them need an adjustment in dosing.

Hahr AJ & Molitch ME. Clin Diabetes Endocrinol 2015;1:2. doi:10.1186/s40842-015-0001-9

image credits